NEW! If you don't understand one of the words in this article,
just double-click it.
A window will open with a definition from CancerWEB's On-line Medical Dictionary. If the double-click feature
doesn't work in your browser, you can enter the word below:
Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.
November 2, 2007
Early Treatment Reduces Risk of Three Common Complications
Does starting HIV treatment early increase the risk of complications like peripheral neuropathy, anemia and kidney problems? On the contrary, say new data from the HIV Outpatient Study (HOPS) to be reported in an upcoming issue of the Journal of Acquired Immune Deficiency Syndromes (JAIDS).
Peripheral neuropathy, anemia and kidney problems are common occurrences in people with HIV, notably those on antiretroviral (ARV) treatment. In turn, some experts have suggested that starting treatment earlier than is currently recommended—a CD4 count below 350 cells—may result in an upswing in these complications among otherwise healthy people living with the virus.
The HOPS investigators, under the direction of Kenneth Lichtenstein, MD, of the University of Colorado in Denver followed 2,165 HIV-positive patients who started ARV treatment with varying CD4 counts for approximately three years. Patients were divided into three groups: those who started with CD4s below 200, between 200 and 349, and 350 or higher.
Among patients starting therapy with CD4s above 200, the number of new cases (incidence) of peripheral neuropathy, anemia and kidney problems—and the risk for these complications—was lower, compared with those starting HIV treatment with CD4s below 200. The incidence and risks of kidney problems were similar among those starting therapy with CD4s above 350 versus 200 to 349, but the risk of peripheral neuropathy and anemia was found to be lower among those starting with 350 or more CD4s.
Dr. Lichtenstein’s group also reported that the incidence of each condition decreased rapidly and remained low the longer patients remained on ARV therapy. The risk of these complications occurring was actually highest during the first three months of treatment, regardless of the pre-therapy CD4 count.
Scroll down to comment on this story.
Please click OK to confirm your comment and confirm you accept our posting rules. Note your message will be reviewed by our staff before going live.
Previous Comments:
comments 1 - 3 (of 3 total)
Tim Horn, AIDSmeds.com, New York, 2007-11-08 21:01:25
Sal - Actually, what the study suggests is that starting therapy with lower CD4s is associated with an *increased* risk of these problems. Actually, this has been found in other studies too -- the lower the CD4 count gets before treatment, the higher the risk of various side effects.
sal, los angeles ca, 2007-11-08 13:51:41
so if im reading this right this means that starting meds with a lower t cell count decreses the chances of aqcuiring neuropathy,enemia,and kidney problems. will someone clearify for me. thanks
leon roiballove, colton, 2007-11-05 08:20:09
I stareted on various arv medication in the past 15 yrs, since being dianosised with hiv, viral load undetected to this day, cd4 greatter than 400. regime Sutiva, epizicom s/s peripheral neuropathy, elevated alt, and fluctuation of blood sugar what else I am to expect beside kidney and anemia. please e-mail.
